


Introduction to the Cell and Gene Therapy Catapult TMRN Seminar Series, 23rd June 2021

Dr Asimina Pantazi & Dr Sam Goldsmith

The Catapult Network

- A long-term investment to transform the UK's ability to create new products and services
- Open up global opportunities for the UK and generate sustained economic growth for the future
- Strategically located at sites across the UK



About us



Established by Innovate UK as a **not-for-profit**, independent centre



Bridge the gap between businesses and academic research



Provide access to unique technical **facilities** and **expertise** to help adopt, develop and exploit innovations



Part of a **world-leading network** of technology and innovation centres

It is our vision for the **UK** to be a **global leader** in the development, delivery and commercialisation of cell and gene therapies.

Where **businesses can start, grow and confidently develop** these transformative therapies, delivering them to patients rapidly and effectively.

Our mission

Accelerate	Complement	Innovate	Facilitate
the commercialisation of innovations from research	industry and academia with unique technical facilities and expertise	in collaboration with academia and industry	operating in UK as a global centre; working with Government, the NHS and international regulators

← **Cell and gene therapy specialists (>300)** →

London	Stevenage	Braintree
1,200m ² centre for industrialising cell and gene therapy manufacture	7,700m ² facility for cell and gene therapy manufacturing at scale	4,627m ² facility to develop technology transfer innovation for industrial scale cell and gene therapy manufacturing
Industrialisation	Regulatory and clinical	Engagement
<ul style="list-style-type: none"> Process development Analytical development Manufacturing systems Supply chain 	<ul style="list-style-type: none"> Regulatory Non-clinical safety Clinical delivery Programme management 	<ul style="list-style-type: none"> Collaboration formation (e.g. consortia and 3-way collabs) Intellectual property and patent Health economics Reimbursement

Our facilities



London

- 1,200m² purpose built centre located on the 12th floor of Guy's Hospital
- Analytical characterisation
- Process development
- Viral vector
- Stem cell differentiation
- 10th floor collaboration laboratory



Stevenage

- 7,700m² facility designed specifically for cell and gene therapy manufacturing at scale
- 12 segregated cleanroom modules
- Secure collaborative model
- At the centre of the third largest cell and gene therapy cluster globally
- Expanded QC capacity and capability



Braintree

- 4,627m² facility to support national COVID-19 vaccine manufacturing
- Fully operational by Dec 2021 to meet immediate vaccines demand
- To become innovation centre for cell and gene therapies and develop technology transfer innovation

How the CGTC operates


Core model: in-kind support, e.g. CoR

Collaborative model: identify and collaboratively apply to grant to carry out work

Commercial model: fee for service

Accelerating the commercialisation of academic research

Foster closer relationship between researchers and industry



Increasing visibility of the UK research base to investors




Develop Investible Opportunities

Academic/NewCo Focus

Innovative Science

Commercial Potential



CoR Evolution

Pre-2019

- Ad hoc identification of innovative academic projects
- Developed successful investible opportunities
- Opportunity to structure & expand offering

2019 Onwards

Active identification of projects

Dedicated CoR team

Structured diligence process and offering

Portfolio of active collaborations

CoR - What is our definition of an investible opportunity?



A great differentiated idea

Convincing in vitro data to support MoA

Relevant in vivo model and endpoints

A reliable high yielding scalable manufacturing process

Pre-clinical Safety & Pharmacology data

An experienced entrepreneurial team


A clear vision of their medical product

A clear realistic Clinical PoC study design

Thorough HEMA model to support value

Freedom To Operate

CoR - Investible Opportunity Development



1. Investible Opportunity Clinic

Use diverse expertise of CoR team to review projects from academics and Spin Outs

- Each person reviews the Investible Opportunity from their respective speciality
- Provides a high level report on what needs to be done to get from amber to green
- Can be used in pitch decks and business plans
- Forms basis of diligence document for 2

2. CoR Collaboration

Formal collaboration with academic group or spin-out


- Desk based WPs
- Lab based WPs
- Focused on getting amber lights green
- Collaborate with 3rd party (VC/Funder)

3. Pitch Training and VC Engagement

Providing template VC pitch decks, dry run pitch training, VC introductions

Collaborating Universities

Bristol – PureSpring
Kings College London
Imperial College
Manchester
Cambridge
Oxford
QMUL
Birmingham
Babraham
Sheffield – Rinri Therapeutics
Leeds
Edinburgh



Grant opportunities

Funding body	Call	Applicant	Funding	Opening	DD
IBioIC	Innovation Fund	Academia – industry collab	£100K	Open	01/07/21
MRC	MRC Development Pathway	Academia, RTO, NHS	£1m	Open	21/07/21
IUK	SMART	SME, acad-RTO collab	£25K-£2m	Open	25/08/21
IUK	BMC	SMEs, acad-RTO collab	£25K-£4m	Open	26/08/21
MRC	MRC experimental medicine grants	Acad, RTO, NHS	No limit	15/07/21	09/09/21
MRC	MRC neurosciences & mental health research programme	Industry-academia collab	£1m+	Open	29/09/21
UKRI	DPFS	Academia, acad-ind collab	No limit	15/10/21	24/11/21

Contact details

Name	Role	email
Asimina Pantazi, PhD	Business Development Executive UK North	asimina.pantazi@ct.catapult.org.uk
Sam Goldsmith, PhD	Sr Manager of Commercialisation of Research	sam.goldsmith@ct.catapult.org.uk

CATAPULT

Cell and Gene Therapy

Cell and Gene Therapy Catapult is committed to ensuring high standards of research integrity and research best practice in the activities we carry out. We subscribe to the principles described in the UK concordat to support research integrity.

Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT. VAT number 154 4214 33.

12th Floor Tower Wing
Guy's Hospital
Great Maze Pond
London SE1 9RT

info@ct.catapult.org.uk
ct.catapult.org.uk
Twitter: @CGTCatapult

